Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1568673

Cover Image

PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1568673

Systemic Lupus Erythematosus Treatment Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

PUBLISHED:
PAGES: 154 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 4850
PDF & Excel (Multi User License)
USD 5350
PDF & Excel (Enterprise User License)
USD 8350

Add to Cart

The Global Systemic Lupus Erythematosus (SLE) Treatment Market will exhibit a 7.6% CAGR during 2024-2032, driven by rising disease prevalence, advancements in treatment modalities, and increased research funding. As per the Lupus Foundation of America, around 1.5 million Americans and at least 5 million people worldwide have a form of lupus, with SLE being the most common. Enhanced diagnostic tools and greater awareness have intensified the demand for effective treatments.

Additionally, the shift towards personalized medicine and precision therapies is transforming the SLE treatment landscape. Advances in genomics and biotechnology have led to treatments tailored to individual patient profiles, enhancing efficacy and minimizing side effects. Increased R and D investments and favorable regulatory frameworks for novel treatments are accelerating the availability of cutting-edge therapies, further boosting the market growth.

The systemic lupus erythematosus (SLE) treatment industry is segmented based on drug class, gender, route of administration, distribution channel, and region.

The biologics segment is witnessing notable growth due to its transformative impact on disease management. Biologics, including monoclonal antibodies and cytokine inhibitors, offer targeted therapies that address specific aspects of the autoimmune response in SLE. The advances in biotechnology and a deeper understanding of SLE's pathophysiology, position biologics as a critical component in the evolving treatment landscape. The segment growth is further supported by ongoing clinical trials and expanding indications for these therapies, promising continued innovation and enhanced management of SLE.

The intravenous (IV) segment will hold a decent market share by 2032, due to rapid onset of action and effectiveness in managing severe disease flares. IV administration allows for direct delivery of medications into the bloodstream, ensuring higher bioavailability and more immediate therapeutic effects. This route is particularly advantageous for biologics and high-dose corticosteroids. The growing adoption of IV therapies is driven by the need for potent and fast-acting treatments to manage complex SLE cases, coupled with advancements in infusion technology and the development of new IV medications tailored to SLE.

Asia Pacific systemic lupus erythematosus (SLE) treatment market is poised to witness impressive growth trends over 2024-2032. Countries such as China, India, and Japan are experiencing higher incidences of SLE, driven by factors such as genetic predispositions, environmental influences, and lifestyle changes. The rising disease burden, combined with the growing availability of advanced treatment options, including biologics and targeted therapies, is fueling market growth. Additionally, governments and healthcare organizations are enhancing efforts to support SLE research and improve patient care infrastructure. As the region continues to develop its healthcare systems and increase access to innovative treatments, the Asia Pacific market value will bolster.

Product Code: 10531

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of SLE
      • 3.2.1.2 Advancements in treatment options
      • 3.2.1.3 Increased government funding and support for research on autoimmune diseases
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High cost of treatment
      • 3.2.2.2 Limited awareness and diagnosis
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Pipeline analysis
  • 3.6 Porter's analysis
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Immunosuppressants
  • 5.3 Corticosteroids
  • 5.4 Biologics
  • 5.5 Antimalarials
  • 5.6 NSAIDs

Chapter 6 Market Estimates and Forecast, By Gender, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Female
  • 6.3 Male

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Oral
  • 7.3 Intravenous
  • 7.4 Subcutaneous

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospital pharmacies
  • 8.3 Retail pharmacies
  • 8.4 Other distribution channels

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
    • 9.3.7 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE
    • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 Anthera Pharmaceuticals, Inc.
  • 10.2 Aurinia Pharmaceuticals, Inc.
  • 10.3 AstraZeneca
  • 10.4 Biogen
  • 10.5 Bristol-Myers Squibb Company
  • 10.6 Eli Lilly and Company
  • 10.7 F. Hoffmann-La Roche Ltd.
  • 10.8 GSK plc.
  • 10.9 ImmuPharma PLC
  • 10.10 Johnson and Johnson Services, Inc.
  • 10.11 Merck and Co., Inc.
  • 10.12 Novartis AG
  • 10.13 Pfizer, Inc.
  • 10.14 Sanofi SA
  • 10.15 Sandoz International GmbH
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!